Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plasma Methylglyoxal Levels & Diabetic CVD

Diabetes Care; ePub 2018 May 21; Hanssen, et al

Plasma methylglyoxal (MGO) and glyoxal (GO) levels are associated with cardiovascular disease (CVD) mortality in individuals with type 2 diabetes, a recent study found. The study included 1,003 participants (mean age 59.1 years, 69.3% male, 61.6% with prior CVD) with type 2 diabetes. Researchers measured plasma MGO levels and 2 other dicarbonyls (GO and 3-deoxyglucosone) as baseline with mass spectrometry. Mean follow-up of CVD events was 8.6 years. Among the findings:

  • 287 individuals suffered from at least 1 CVD event; 346 died, and 60 underwent an amputation.
  • Higher MGO levels were associated with total and fatal CVD and with all-cause mortality, myocardial infarction, and amputations.
  • MGO levels were not associated with stroke.
  • Higher GO levels were significantly associated with fatal CVD, but not with other outcomes.


Hanssen NMJ, Westerink J, Scheijen JJM, et al. Higher plasma methylglyoxal levels are associated with incident cardiovascular disease and mortality in individuals with type 2 diabetes. [Published online ahead of print May 21, 2018]. Diabetes Care. doi:10.2337/dc18-0159.